Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | GNAI3 | P08754 | 9/20 | 0.60 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.60 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2134122 | 0.87 | L3MBTL1 (0.83) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL6285463 | 0.87 | L3MBTL1 (0.83) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL23471439 | 0.85 | L3MBTL1 (0.69) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL4450061 | 0.85 | L3MBTL1 (0.80) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL8972823 | 0.85 | L3MBTL1 (0.80) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL8972813 | 0.85 | L3MBTL1 (0.80) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL7060548 | 0.85 | L3MBTL1 (0.80) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL1045855 | 0.85 | L3MBTL1 (0.80) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL8972980 | 0.85 | L3MBTL1 (0.80) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL768398 | 0.85 | L3MBTL1 (0.80) | L3MBTL1MEN1KMT2ATDP1GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023217764-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2023-11-16 | — | — | WO | claimed |
| US-20210177811-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2021-06-17 | — | — | US | claimed |
| CN-111344013-A | Use of NOX inhibitors for the treatment of cancer | 吉恩基奥泰克斯瑞士股份有限公司 | 2020-06-26 | — | — | CN | claimed |
| EP-3479843-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | GenKyoTex Suisse SA (CH) | 2019-05-08 | — | — | EP | claimed |
| US-12011436-B2 | Use of NOX inhibitors for treatment of cancer | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2024-06-18 | — | — | US | disclosed |
| WO-2023217764-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2023-11-16 | — | — | WO | disclosed |
| US-20210177811-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2021-06-17 | — | — | US | disclosed |
| CN-111344013-A | Use of NOX inhibitors for the treatment of cancer | 吉恩基奥泰克斯瑞士股份有限公司 | 2020-06-26 | — | — | CN | disclosed |
| EP-3479843-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | GenKyoTex Suisse SA (CH) | 2019-05-08 | — | — | EP | disclosed |
| CN-102137668-B | Pyrazolopyridine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX S.A. (CH) | 2016-05-18 | — | — | CN | disclosed |
| EP-2342203-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-11-04 | — | — | EP | disclosed |
| EP-2674160-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-10-28 | — | — | EP | disclosed |
| CN-101686967-A | Pyrazolopyridine Derivatives as NADPH Oxidase Inhibitors | GENKYO TEX | 2010-03-31 | — | — | CN | disclosed |
| EP-2165707-A1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYO TEX SA (CH) | 2010-03-24 | — | — | EP | disclosed |
| EP-2166009-A1 | Pyrazolo pyridine derivatives as nadph oxidase inhibitors | GENKYO TEX SA (CH) | 2010-03-24 | — | — | EP | disclosed |
| EP-2166008-A1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYO TEX SA (CH) | 2010-03-24 | — | — | EP | disclosed |
| US-20100048560-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-02-25 | — | — | US | disclosed |
| EP-2139477-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-01-06 | — | — | EP | disclosed |
| EP-2002835-A1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GenKyo Tex (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008113856-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048560-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | L3MBTL1 4817/4885MEN1 4672/4885KMT2A 3540/4885 |
| US-12011436-B2 | Use of NOX inhibitors for treatment of cancer | NOX1, NOX5, NOX3 | L3MBTL1 3647/4885MEN1 4605/4885KMT2A 2397/4885 |
| US-20210177811-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | NOX1, NOX5, NOX3 | L3MBTL1 3647/4885MEN1 4605/4885KMT2A 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.